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Letters
RESEARCH LETTER
Association ofMediterraneanDietWith Peripheral
Artery Disease: The PREDIMEDRandomized Trial
The role of nutrition in preventing peripheral artery disease
(PAD) remains elusive.1
Mediterranean diets reduce the risk ofmyocardial infarc-
tion and stroke.2,3 They also may reduce the risk of PAD, but
this hypothesis has never been tested in a randomized trial.
We assessed the association of Mediterranean diets with the
occurrence of symptomatic PAD in an exploratory, nonpre-
specified analysis of a randomized trial.
Methods |ThePrevenciónconDietaMediterránea (PREDIMED)
was a multicenter, randomized, primary prevention feeding
trialwithblindedassessmentof endpoints conducted inSpain
between October 2003 and December 2010.3,4
Eligible participants were men aged 55 to 80 years and
women aged 60 to 80 years without clinical PAD or baseline
cardiovascular disease but with type 2 diabetesmellitus or at
least 3 cardiovascular risk factors.
Participantswererandomized ina1:1:1 ratio to1of3groups:
aMediterraneandiet supplementedwithextra-virginoliveoil;
a Mediterranean diet supplemented with nuts; or counseling
on a low-fat diet (control group). All participants received a
comprehensivedietaryeducationalprogramonaquarterlyba-
sis. The intensityof theprogramdelivered to the control group
was increased in October 2006.
Theprotocolwas approvedby institutional reviewboards
and written informed consent was obtained from all partici-
pants.
New symptomatic PAD events were confirmed by a
central end-point adjudication committee that was blinded
to the allocated group. A confirmed diagnosis of PAD
in symptomatic patients required at least 1 of the following
criteria: an ankle-brachial index of less than 0.9 at rest, a
clinical diagnosis of arterial occlusive disease based on
imaging tests (duplex ultrasonography, magnetic resonance
angiography, computed tomographic angiography, or
catheter–based radiocontrast angiography), or an endovas-
cular or open surgical procedure (revascularization or
amputation).
WeusedStata version 12.1 (StataCorp) for statistical analy-
ses. Kaplan-Meier curves andCox proportional hazardsmod-
els adjusted for baseline factorswereused to compare the risk
ofPADforeachdiet groupvs thecontrol grouponan intention-
to-treat basis.
Thenumberneeded to treat (NNT)was estimated for each
diet group vs control group. As a sensitivity analysis, we used
multiple imputation algorithms for participants without any
events or study contact for at least 2 years.
Results | Of 8713 eligible candidates, 7477 were initially in-
cludedand randomized in thePREDIMEDtrial.3Among them,
12 participants were excluded for intermittent claudication
symptoms at baseline.
Table. Incident Peripheral Artery Disease by Intervention Group
Mediterranean Diet
ControlExtra-Virgin Olive Oil Nuts
No. of patients 2539 2452 2444
No. of cases 18 26 45
Person-years of follow-up 11 796 10 329 9676
Crude rate/1000 person-years (95% CI) 1.5 (1.0-2.4) 2.5 (1.7-3.7) 4.7 (3.5-6.2)
Hazard ratios of PAD by intervention group (95% CI)a
Model
Crude 0.32 (0.19-0.56) 0.51 (0.32-0.83) 1 [Reference]
Age and sex adjusted 0.31 (0.18-0.54) 0.48 (0.29-0.78) 1 [Reference]
Multivariable adjustedb 0.34 (0.20-0.58) 0.50 (0.30-0.81) 1 [Reference]
Multivariable adjustedc 0.36 (0.20-0.62) 0.52 (0.32-0.86) 1 [Reference]
Multivariable adjustedd 0.36 (0.21-0.65) 0.54 (0.32-0.92) 1 [Reference]
Abbreviation: PAD, peripheral artery disease.
a Stratified by center.
bAdjusted for age, sex, smoking (current or former), diabetes, hypertension,
and hyperlipidemia.
c Additionally adjusted for height, waist circumference, bodymass index,
baseline adherence to theMediterranean diet (14-point score), leisure-time
physical activity (metabolic equivalent tasks in minutes/day), educational level
(illiterate or elementary education vs secondary education or university),
hormone therapy, antiplatelet therapy, statins, angiotensin-converting
enzyme inhibitors, β-blockers, diuretics, insulin, other hypoglycemic agents,
total vitamin D intake, dietary vitamin B12 intake, dietary folic acid intake, and
family history of premature cardiovascular disease.
d Complete case analysis excluding 514 participants for whom there was no
documented event or who were lost to follow-up for 2 years or longer.
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The mean (SD) age of included participants was 67 (6.2)
years, and 58% were women. We observed 89 confirmed
new cases of clinical PAD after a median follow-up of 4.8
years.
Both Mediterranean diet interventions were associated
with a lower risk of PAD compared with the control group
(Table). In the model adjusted for classic atherosclerotic risk
factors, the hazard ratio (HR)was 0.34 (95%CI, 0.20-0.58) for
participants in theMediterranean diet plus extra-virgin olive
oil group and 0.50 (95% CI, 0.30-0.81) for the Mediterranean
diet plus nuts group vs control group.
The multiple imputation procedure rendered similar es-
timates. No statistically significant difference between the 2
active intervention groups was apparent (adjusted HR, 0.71;
95% CI, 0.38-1.33).
TheKaplan-Meiercurvesdivergedearly inthetrial (Figure).
The NNT to prevent 1 case of PAD per year was 336 (95% CI,
269-566) for theMediterranean diet plus extra-virgin olive oil
group and 448 (95% CI, 316-1536) for the Mediterranean diet
plus nuts group.
Discussion |To our knowledge, this is the first randomized pri-
mary prevention trial to suggest an association between a di-
etary intervention and PAD. These results are consistentwith
previous observational studies and relevant from a public
health perspective.5,6
Because PADwas not a prespecified end point in the trial
protocol, this is only an exploratory analysis. Other potential
limitations include that the observed number of events was
small and the study was restricted to clinically symptomatic
cases.Replicationbyanother randomizedcontrolled trialwith
PAD as a prespecified end point is needed before causal con-
clusions can be drawn.
The randomized design, blinded assessment and adjudi-
cation of events, and adjustment for a large number of poten-
tial confounders minimize the threat of biases in this study.
We cannot ascertain whether the observed association
is due to a reduced incidence of asymptomatic PAD (true
primary prevention) or to a reduced conversion from this
early stage of PAD to symptomatic and clinically meaningful
PAD.
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COMMENT&RESPONSE
Hormone TherapyUse andOutcomes
in theWomen’s Health Initiative Trials
To the Editor The study by Dr Manson and colleagues1 pro-
vided considerable information about the 2 Women’s Health
Initiative (WHI) hormone trials, especially regarding out-
comes stratified by the age of the participants at the time of
trial entry.
During the intervention phase of theWHI Estrogen-Alone
Trial, participants aged 50 to 79 years randomized to conju-
gated equine estrogens (CEE) had significantly worse out-
comes for stroke, deep venous thrombosis, urinary inconti-
nence, and gallbladder disease.1 Information on all of these
outcomes (stratifiedbyageof theparticipantsbydecadeat trial
entry) for the intervention phase has been published,1-4 ex-
cept for data on gallbladder disease.
Gallbladder outcomes have been reported for WHI par-
ticipants using a semiannual safety questionnaire and, if pre-
sent, confirmed by an examination of medical and hospital
records.5Therewas“asuggestion” (P = .06) forgallbladderdis-
ease outcomes to vary by age in theWHIEstrogen-AloneTrial
intervention phase5 but no decade-specific information has
been published.
Could theauthorsprovidegallbladderdiseaseoutcome in-
formationstratifiedbydecadeofage for the interventionphase
of theWHIEstrogen-AloneTrial? Thesedata could assist phy-
sicians in assessing the risk to benefit ratio of CEE mono-
therapy in younger women without a uterus.
In addition, could the authors clarify the data for the
gallbladderendpointused in their study,whichshows461gall-
bladder events in theCEEgroup and 312 events in the placebo
group in the intervention phase?
The one prior WHI publication with gallbladder disease
data showed many fewer outcomes, with 228 gallbladder
events for the CEE group and 143 for the placebo group.5
Also, in the prior publication,5 the annualized incidence
percentage for gallbladder events is reported as 0.78% for
the CEE group, whereas in the study by Manson et al,1 the
annualized incidence percentage for the CEE group is
reported as 1.64%.
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In Reply Dr Roehm requests more information about the
gallbladder disease outcome in the WHI trials. The
goal of our article was to provide a comprehensive, inte-
grated overview of findings from the 2 hormone therapy
trials, including results from extended postintervention
follow-up.
Due to the large number of outcomes presented (includ-
ing primary and secondary adjudicated end points and
quality-of-life outcomes), we only had space to present age-
stratified analyses for the primary and secondary outcomes.
We presented the hazard ratio (HR) for gallbladder disease
in the overall cohort for each trial and noted that no signifi-
cant differences by age group were observed.
As requested by Roehm,we present the detailed findings
for gallbladderdiseasebyagegroup for bothhormone therapy
trials (Table). Tests for interaction by age group were not sta-
tistically significant (P = .66 for both trials).
Our results for gallbladder disease in the overall cohort
are nearly identical to those previously presented by Cirillo
et al.1 Cirillo et al reported an HR of 1.59 (95% CI, 1.28-1.97)
for gallbladder procedure/disease (confirmed by hospitaliza-
tion records) in the WHI trial of CEE plus medroxyprogester-
one acetate (MPA) compared with an HR of 1.57 (95% CI,
1.36-1.80) in our analyses based on self-reported diagnosis
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